Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Earnings Per Share Diluted of $2.01 (loss) per share for the year ending 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +26.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from ROCKET PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.45 (loss) per share | Q2 2020: $0.45 (loss) per share | Q3 2020: $0.53 (loss) per share | Q1 2021: $0.65 (loss) per share | Q2 2021: $0.55 (loss) per share | Q3 2021: $0.79 (loss) per share | Q1 2022: $0.67 (loss) per share | Q2 2022: $0.83 (loss) per share | Q3 2022: $0.87 (loss) per share | Q1 2023: $0.73 (loss) per share | Q2 2023: $0.82 (loss) per share | Q3 2023: $0.75 (loss) per share | Q1 2024: $0.66 (loss) per share | Q2 2024: $0.74 (loss) per share | Q3 2024: $0.71 (loss) per share | Q1 2025: $0.56 (loss) per share | Q2 2025: $0.62 (loss) per share | Q3 2025: $0.45 (loss) per share.
- Over the full 7 years of available data (2019 to 2025), ROCKET PHARMACEUTICALS, INC.'s Earnings Per Share Diluted has declined by 27.2%.
- Historical annual values: Fiscal year 2025: $2.01 (loss) per share | Fiscal year 2024: $2.73 (loss) per share | Fiscal year 2023: $2.92 (loss) per share | Fiscal year 2022: $3.26 (loss) per share | Fiscal year 2021: $2.67 (loss) per share | Fiscal year 2020: $2.52 (loss) per share | Fiscal year 2019: $1.58 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: